| |
pfmdr1 CN
|
% CN >1.5
|
|---|
| |
1
|
2
|
3
|
4
|
(95% CI)a
|
OR (95% CI)a
|
|---|
|
Karen State (n = 40)
|
33
|
6
|
0
|
1
|
17.5 (0–54.3)
| |
|
Clinic
|
21
|
0
|
0
|
0
|
0.0
| |
|
Screening
|
12
|
6
|
0
|
1
|
35.0
|
n/a
|
|
Kachin State (n = 18)
|
16
|
2
|
0
|
0
|
9.6 (0–31.6)
| |
|
Clinic
|
5
|
1
|
0
|
0
|
16.7
| |
|
Screening
|
11
|
1
|
0
|
0
|
8.3
|
0.5 (0.0–7.8)b
|
|
Chin-Mizoram (n = 115)
|
104
|
11
|
0
|
0
|
11.1 (0–32.1)
| |
|
Clinic
|
76
|
6
|
0
|
0
|
7.3
| |
|
Screening
|
28
|
5
|
0
|
0
|
15.2
|
2.3 (1.1-4.7)b
|
|
Screening vs clinicalTotal (n = 173)
|
153
|
19
|
0
|
1
|
11.6 (2.7-20.4)
| |
|
Clinic
|
102
|
7
|
0
|
0
|
6.4
| |
|
Screening
|
51
|
12
|
0
|
1
|
20.3
|
3.7 (1.1-12.5)b
|
|
Anti-malarial treatment Total (n = 168)
|
148
|
20
|
0
|
1
| | |
|
No treatment in past 8 weeks
|
117
|
17
|
0
|
1
|
12.7
| |
|
Treatment in past 8 wks
|
31
|
3
|
0
|
0
|
8.8
|
0.7 (0.1-3.1)c
|
- aCIs adjusted for clustering within study site (n = 13).
- bOR = odds of pfmdr1 amplification among screening participants/odds of amplification among febrile clinical patients.
- c OR = odds among participants reporting treatment in past 8 weeks/odds among those not reporting treatment in previous eight weeks.
